Mitoxantrone Hydrochloride Liposome
Phase 3Small molecule
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Mitoxantrone Hydrochloride Liposome is one of 278 small molecule programs targeting Acute Myeloid Leukemia (AML). It is currently in Phase 3.
11
Indications
45
Total Trials
18
Active Trials
277
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
401 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Mitoxantrone Hydrochloride Liposome
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diffuse Large B-Cell Lymphoma6 trials
R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT05784987·60 enrolled
R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT05777369·30 enrolled
Show 3 more trials
Lymphoma5 trials
Treatment3 trials
VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06447090·30 enrolled
Breast Cancer3 trials
Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer
Unknown status·—·N/A·NCT06156761·24 enrolled
Nasopharyngeal Carcinoma2 trials
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment
Not yet recruiting·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·Phase 3·NCT05717764·500 enrolled
21 more indications
Relapsed/Refractory2 trials
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06489808·89 enrolled
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL
Active, not recruiting·CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT04668690·193 enrolled
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT04668690·193 enrolledNewly Diagnosed2 trials
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT07486479·204 enrolled
Patients With Advanced Solid Tumors2 trials
Acute Myeloid Leukemia2 trials
Lip2 trials
Malignant Tumor1 trial
Recurrent or Metastatic NPC1 trial
Ovarian Cancer1 trial
Neuromyelitis Optica1 trial
Dexamethasone1 trial
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
Unknown status·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·Phase 1·NCT05052970·60 enrolled
Advanced Solid Tumor1 trial
Metastatic Head and Neck Cancer1 trial
Soft Tissue Sarcoma1 trial
Pancreatic Cancer1 trial
Gastric Carcinoma1 trial
Multiple Sclerosis1 trial
Induction Therapy1 trial
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
Recruiting·—·Phase 2·NCT06221683·500 enrolled
Acute Myeloid Leukemia (AML)1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details